Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Remicade

Executive Summary

Remicade (infliximab) growth will continue in face of Abbott's roll out of Humira, Johnson & Johnson says. "We expect to see continued solid growth through the balance of this year, and we expect to be able to compete very effectively with both Humira and Enbrel," J&J Company Group Chairman in Charge of Biologics Franchise Joseph Scodari says. "Remicade is likely the most potent drug in this category, and that is by far and away the focal point of our clinical positioning," Scodari adds. U.S. Remicade sales were $345 mil. for the first quarter, a 46% increase...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS041696

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel